Emerging innovations in clinical trial design

DA Berry

Type: Review

Publication Date: 2015-11-11

Citations: 42

DOI: https://doi.org/10.1002/cpt.285

View Publication

Locations

Clinical Pharmacology & Therapeutics - View
PubMed - View

Similar Works

Action	Title	Year	Authors
+	Innovation in oncology clinical trial design	2019	Jaap Verweij Hans R. Hendriks H. Zwierzina Hanauske Volker Wacheck Olivier Collignon Paolo Bruzzi Jenny Gross Todd Riehl Frank Bretz
+ PDF Chat	The Evolution of Clinical Trials in Oncology: Defining Who Benefits from New Drugs Using Innovative Study Designs	2017	Richard M. Goldberg Lai Wei Soledad Fernández
+	Clinical Trial Designs in Oncology	2020	Edward L. Korn Boris Freidlin
+	Clinical Trial Design Considerations in the Era of Targeted Therapy	2019	Rajeshwari Sridhara
+ PDF Chat	The Future of Clinical Trial Design in Oncology	2021	Anna Spreafico Aaron R. Hansen Albiruni R. Abdul Razak Philippe L. Bédard Lillian L. Siu
+	Clinical trial design in oncology	2004	Richard Sullivan
+	Evolving challenges in clinical trials design	2022	Colin B. Begg
+	Controversies Related to Oncology Clinical Trial Development	2014	Elihu H. Estey
+	Common misconceptions of randomized controlled trials in oncology	2022	Kerrington Powell Vinay Prasad
+ PDF Chat	A Review of Perspectives on the Use of Randomization in Phase II Oncology Trials	2019	Michael J. Grayling Munyaradzi Dimairo Adrian Mander Thomas Jaki
+	Overview of Classical Design in Biomarker-Informed Clinical Trials	2019	Bo Huang Jing Wang Robert A. Beckman Sandeep Menon Weidong Zhang
+	Genomic Alteration–Driven Clinical Trial Designs in Oncology	2016	Richard Simon
+	Clinical Trial Designs for Approval of New Anticancer Agents	2013	Manpreet Chadha Daniel D. Von Hoff
+	Clinical trials in oncology	2022	Gareth Griffiths
+	Clinical trials in oncology	2008	Gareth Griffiths
+	Clinical trials in oncology	2011	Gareth Griffiths Loretta Sweeney
+	Clinical trials in oncology	2016	Gareth Griffiths
+	Clinical trial design in cancer	1979	Richard F. Mould
+	Testing oncological treatments in the era of personalized medicine	2016	David Teira
+	The Evolution of Clinical Trials in Oncology: Randomised Controlled Trials to Real World Studies	2014	G.H. Lyman

Works That Cite This (16)

Action	Title	Year	Authors
+	The Bayesian Time Machine: Accounting for temporal drift in multi-arm platform trials	2022	Benjamin R. Saville Donald A. Berry Nicholas Berry Kert Viele Scott Berry
+	Bayesian clinical trials at The University of Texas MD Anderson Cancer Center: An update	2019	Rebecca S.S. Tidwell S. Andrew Peng Minxing Chen Diane D. Liu Ying Yuan J. Jack Lee
+ PDF Chat	The Evolution of Master Protocol Clinical Trial Designs: A Systematic Literature Review	2020	Elias Laurin Meyer Peter Mesenbrink Cornelia Dunger‐Baldauf Hans‐Jürgen Fülle Ekkehard Glimm Yuhan Li Martin Posch Franz König
+ PDF Chat	Adaptive trial designs for spinal cord injury clinical trials directed to the central nervous system	2020	M.J. Mulcahey Linda Jones Frank W. Rockhold R. Rupp John L. K. Kramer Steven Kirshblum Andrew R. Blight Daniel P. Lammertse James D. Guest John D. Steeves
+	Beyond Randomized Clinical Trials: Use of External Controls	2019	Heinz Schmidli Dieter A. Häring Marius Thomas Adrian Cassidy Sebastian Weber Frank Bretz
+ PDF Chat	COVID-19 pandemic surges can induce bias in trials using response adaptive randomization: A simulation study	2022	Christopher J. Yarnell Robert Fowler Lillian Sung George Tomlinson
+ PDF Chat	How to conduct well-designed clinical research	2022	Da Jung Kim Song Yi Kil Jongwon Son Ho Sup Lee
+ PDF Chat	Lecanemab for Patients With Early Alzheimer Disease	2023	Donald A. Berry Shobha Dhadda Michio Kanekiyo David Li Chad J. Swanson Michael C. Irizarry Lynn D. Kramer Scott Berry
+	University of Pennsylvania ninth annual conference on statistical issues in clinical trials: Where are we with adaptive clinical trial designs? (afternoon panel discussion)	2017	Jason T. Connor Angela DeMichele Janet Wittes
+ PDF Chat	First‐in‐Human, Healthy Volunteers Integrated Protocol of <scp>ETC</scp>‐206, an Oral Mnk 1/2 Kinase Inhibitor Oncology Drug	2019	Vincenzo Teneggi Veronica Novotny‐Diermayr Lay Hoon Lee Maryam Yasin Pauline Yeo Kantharaj Ethirajulu S. Gan Stéphanie Blanchard Ranjani Nellore Dhananjay N. Umrani

Works Cited by This (24)

Action	Title	Year	Authors
+	Application of Adaptive Design Methodology in Development of a Long-Acting Glucagon-like Peptide-1 Analog (Dulaglutide): Statistical Design and Simulations	2012	Zachary Skrivanek Scott Berry Donald A. Berry Jenny Y. Chien Mary Jane Geiger James H. Anderson Brenda Gaydos
+	Adaptive Bayesian Designs for Dose-Ranging Drug Trials	2002	Donald A. Berry Peter Müller Andrew P. Grieve Michael K. Smith Tom Parke Richard Blazek Neil Mitchard Michael Krams
+	Stein's Paradox in Statistics	1977	Bradley Efron Carl N. Morris
+	I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy	2009	AD Barker C C Sigman Kelloff Gj NM Hylton DA Berry L. Esserman
+ PDF Chat	Bayesian Statistics and the Efficiency and Ethics of Clinical Trials	2004	Donald A. Berry
+	Sequential Medical Trials	1963	F. J. Anscombe
+ PDF Chat	Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center	2009	Swati Biswas Diane D. Liu J. Jack Lee Donald A. Berry
+	Adaptive clinical trials in oncology	2011	Donald A. Berry
+ PDF Chat	Optimal two-stage designs for phase II clinical trials	1989	Richard Simon
+	Statistics: A Bayesian Perspective	1995	Donald A. Berry